Short-Course Chemotherapy with TMC207 and Rifapentine in a Murine Model of Latent Tuberculosis Infection
- 15 September 2011
- journal article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 184 (6), 732-737
- https://doi.org/10.1164/rccm.201103-0397oc
Abstract
Multidrug-resistant and extensively drug-resistant tuberculosis (MDR/XDR-TB) is an emerging global health threat. Proper management of close contacts of infectious patients is increasingly important. However, no evidence-based recommendations for treating latent TB infection (LTBI) after MDR/XDR-TB exposure (DR-LTBI) exist. An ultrashort regimen for LTBI caused by drug-susceptible strains (DS-LTBI) is also desirable. TMC207 has bactericidal and sterilizing activity in animal models of TB and improves the activity of current MDR-TB therapy in patients. The objective of this study was to determine whether TMC207 might enable short-course treatment of DR-LTBI and ultrashort treatment of DS-LTBI. Using an established experimental model of LTBI chemotherapy in which mice are aerosol-immunized with a recombinant bacillus Calmette-Guérin vaccine before low-dose aerosol infection with Mycobacterium tuberculosis, the efficacy of TMC207 alone and in combination with rifapentine was compared with currently recommended control regimens as well as once-weekly rifapentine + isoniazid and daily rifapentine ± isoniazid. Outcomes included monthly lung colony-forming unit counts and relapse rates. Lung colony-forming unit counts were stable at about 3.75 log(10) for up to 7.5 months postinfection in untreated mice. Rifamycin-containing regimens were superior to isoniazid monotherapy. TMC207 exhibited sterilizing activity at least as strong as that of rifampin alone and similar to that of rifampin + isoniazid, but daily rifapentine +/- isoniazid was superior to TMC207. Addition of TMC207 to rifapentine did not improve the sterilizing activity of rifapentine in this model. TMC207 has substantial sterilizing activity and may enable treatment of DR-LTBI in 3-4 months.Keywords
This publication has 26 references indexed in Scilit:
- Weekly Moxifloxacin and Rifapentine Is More Active Than the Denver Regimen in Murine TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Rifapentine, Moxifloxacin, or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse ModelAmerican Journal of Respiratory and Critical Care Medicine, 2005
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisScience, 2005
- Paucibacillary Tuberculosis in Mice after Prior Aerosol Immunization with Mycobacterium bovis BCGInfection and Immunity, 2004
- Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.2002
- Limited Tolerability of Levofloxacin and Pyrazinamide for Multidrug-Resistant Tuberculosis Prophylaxis in a Solid Organ Transplant PopulationPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002
- Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.2000
- Asymptomatic Hepatitis in Persons Who Received Alternative Preventive Therapy with Pyrazinamide and OfloxacinClinical Infectious Diseases, 1997
- Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosisTubercle and Lung Disease, 1997
- Limited Tolerance of Ofloxacin and Pyrazinamide Prophylaxis against TuberculosisNew England Journal of Medicine, 1994